What is B. Riley’s Forecast for DNLI FY2029 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – B. Riley issued their FY2029 EPS estimates for shares of Denali Therapeutics in a research note issued on Wednesday, March 5th. B. Riley analyst M. Mamtani expects that the company will earn $0.87 per share for the year. B. Riley has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08.

DNLI has been the subject of a number of other research reports. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a report on Friday, February 28th. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research note on Monday, December 16th. Morgan Stanley began coverage on shares of Denali Therapeutics in a research report on Friday. They set an “overweight” rating and a $33.00 price target on the stock. JPMorgan Chase & Co. lowered their price objective on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $31.00 target price for the company. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.27.

Denali Therapeutics Stock Up 2.6 %

Shares of DNLI opened at $16.69 on Thursday. Denali Therapeutics has a 52-week low of $14.01 and a 52-week high of $33.33. The stock has a fifty day simple moving average of $20.88 and a two-hundred day simple moving average of $24.35. The company has a market capitalization of $2.40 billion, a PE ratio of -6.05 and a beta of 1.43.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC increased its stake in Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock valued at $36,000 after purchasing an additional 1,516 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Denali Therapeutics in the 4th quarter valued at $62,000. Point72 Hong Kong Ltd acquired a new stake in Denali Therapeutics during the 4th quarter worth $65,000. Quest Partners LLC acquired a new stake in Denali Therapeutics during the 3rd quarter worth $73,000. Finally, PNC Financial Services Group Inc. lifted its position in Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after acquiring an additional 885 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insiders Place Their Bets

In related news, insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the transaction, the insider now owns 178,580 shares in the company, valued at $3,610,887.60. The trade was a 6.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the transaction, the director now directly owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock worth $973,442 over the last three months. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.